DNAY CODEX DNA INC

Telesis Bio to Report Third Quarter Financial Results on Monday, November 13, 2023

Telesis Bio to Report Third Quarter Financial Results on Monday, November 13, 2023

SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) --  (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2023 financial results on Monday, November 13, 2023, after the market closes.

The press release can be accessed via the Investor section of Telesis Bio’s website at .

About Telesis Bio

Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Telesis Bio is enabling rapid, accurate and reproducible writing of DNA and mRNA for numerous downstream markets. The award-winning BioXp® system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Telesis Bio is a public company based in San Diego. For more information, visit

Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp are trademarks of Telesis Bio Inc.

Contact:

William J. Kullback

Chief Financial Officer



EN
07/11/2023

Underlying

DNAYCODEX DNA INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CODEX DNA INC

 PRESS RELEASE
Free
DNAY CODEX DNA INC

Telesis Bio Announces Reverse Stock Split

Telesis Bio Announces Reverse Stock Split SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (the Company) (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced that it will effect a 1-for-18 reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on Thursday, May 9, 2024, and the Company's common stock will open for trading on The Nasdaq Global Select Market on May 9, 2024 ...

May 6, 2024 1 EN
 PRESS RELEASE
Free
DNAY CODEX DNA INC

Telesis Bio Inc. announces strategic focus on game-changing Gibson SOL...

Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadership SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated benchtop DNA and mRNA synthesis solutions, today announced a focus in strategy enabled by the commercial availability of its groundbreaking Gibson SOLA platform. Going forward, the company will increasingly concentrate its efforts on expanding the adoption of Gibson SOLA for both DNA and mRNA high throughput drug discovery appl...

April 18, 2024 1 EN
 PRESS RELEASE
Free
DNAY CODEX DNA INC

Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Result...

Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the fourth quarter and year ended December 31, 2023. Results highlight strong BioXp® kit sales, expanding gross margin and reduced operating expense. In discussing the results, Todd R. Nelson Ph.D., Founder and CEO of Telesis Bi...

March 28, 2024 1 EN
 PRESS RELEASE
Free
DNAY CODEX DNA INC

Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financia...

Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results Telesis Bio announces Q4 and full-year 2023 select preliminary financial results, highlighting strong BioXp kit sales, expanding gross margin and reduced expense SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible and rapid automated synthesis in their own lab, today announced certain preliminary, unaudited financial results for the fourth quarter and year ...

February 26, 2024 1 EN
 PRESS RELEASE
Free
DNAY CODEX DNA INC

Telesis Bio Reports Third Quarter 2023 Financial Results

Telesis Bio Reports Third Quarter 2023 Financial Results SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the third quarter of 2023. “This quarter, we continued to drive adoption of our instruments and kits, make progress against important collaborations, advance our mRNA strategy, and strengthen both our Board of Directors and Management Team,” said Todd R. Nelson, PhD, CEO, and founder of Telesis Bio. Highlights Strengthened board of directors and manage...

November 13, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch